Open Heart

MARCH 28, 2025

Methods Relevant studies examining arrhythmia in both exercise and pharmacological stress testing were searched for in PubMed, Embase and Cochrane databases from inception to 14 June 2023. Objectives To determine the significance of stress test-induced arrhythmias.

Arrhythmia 75

Arrhythmia Coronary Artery Disease Myocardial Infarction Atrial Fibrillation 75

Frontiers in Cardiovascular Medicine

JUNE 26, 2025

Novel therapeutic strategies, including lifestyle modifications, pharmacological interventions, and gut microbiota modulation, are discussed. Advanced imaging techniques, notably the perivascular fat attenuation index (FAI) and circulating biomarkers, are highlighted for early CVD detection.

Cardiovascular Disease 52

Cardiovascular Disease Pharmacology Biomarkers Obesity 52

Frontiers in Cardiovascular Medicine

MARCH 20, 2025

The control group received conventional antiarrhythmic therapy with -blockers or propafenone, and the EECP group underwent EECP therapy in conjunction with pharmacological treatment. Patients were randomly assigned to either the control group (n=50) or the EECP group (n=50) in this randomized controlled trial.

Atrial Fibrillation 59

Atrial Fibrillation Blood Pressure Pharmacology Ultrasound 59

Frontiers in Cardiovascular Medicine

JANUARY 23, 2025

The primary electrophysiological mechanism of atrial fibrillation (AF) maintenance is poorly defined. AF mapping studies readily record focal activations (defining them as focal sources or breakthroughs) and incomplete reentries (defining them as reentries or would-be-reentries) but do not or rarely detect complete circular activations.

Atrial Fibrillation 52

Atrial Fibrillation Pharmacology Electrophysiology 52

Journal of the American Heart Association

FEBRUARY 25, 2025

In this scientific statement from the American Heart Association, we redefine maternal cardiovascular health to include psychological health, provide robust evidence on the association of psychological health with cardiovascular outcomes, highlight the social and environmental underpinnings, and finally, offer guidance about how to integrate psychological (..)

Pharmacology 75

Pharmacology Outcomes 75

Heart BMJ

MAY 23, 2025

Despite therapeutic advances in pharmacological and invasive management, studies show that older patients with NSTEMI experience worse in-hospital and long-term outcomes than younger patients, suggesting a clear need for robust evidence in this cohort. In the UK, there are ~20 000 NSTEMI cases annually in patients aged ≥75 years.

Myocardial Infarction 52

Myocardial Infarction Pharmacology Outcomes Hospital 52

Medical Xpress - Cardiology

JANUARY 10, 2025

A research team in the Department of Pharmacology and Pharmacy, LKS Faculty of Medicine, the University of Hong Kong (HKUMed), found that hip fractures not only result in both physical and psychological injuries, but may also induce adverse cardiovascular events.

Heart Failure 64

Heart Failure Pharmacology Research 64

Journal of Clinical Investigation - Cardiology

APRIL 1, 2025

These findings show that the GGT domain of LH2 is protumorigenic, identify Col6 as a candidate effector, and provide a rationale to develop pharmacological strategies that target LH2s GGT domain in cancer cells. Thus, LH2 glucosylates Col6 to drive LUAD progression.

Cancer 59

Cancer Pharmacology 59

Frontiers in Cardiovascular Medicine

JANUARY 28, 2025

Furthermore, we utilized mass spectrometry analysis, network pharmacology, and lipidomics to predict the potential mechanisms of FFDS in the treatment of SCHD.ResultsFollowing treatment, FFDS demonstrated significant improvements in serum triglyceride levels (P=0.013) and a reduction in the frequency of angina episodes (P=0.021).

Heart Disease 52

Heart Disease Angina Cholesterol Pharmacology 52

Frontiers in Cardiovascular Medicine

FEBRUARY 10, 2025

Therefore, optimal secondary prevention includes managing BP through lifestyle changes and pharmacological therapy. Several modifiable risk factors, including increased blood pressure (BP), significantly contribute to cardiovascular risk in CCS.

Blood Pressure 52

Blood Pressure Pharmacology Document Risk Factors 52

European Journal of Heart Failure

JUNE 18, 2025

The concept of HF with improved ejection fraction (HFimpEF) underscores this complexity, identifying patients who exhibit an increase in left ventricular ejection fraction (LVEF) following time and/or pharmacological and device-based therapies.

Heart Failure 68

Heart Failure Document Genetic predisposition Pharmacology 68

Frontiers in Cardiovascular Medicine

FEBRUARY 17, 2025

Long-term management approaches for INOCA patients, including pharmacologic therapies and lifestyle interventions, are reviewed. The paper discusses a potential interference between vasodilators used in trans-radial access and coronary spasm testing.

Ischemia 52

Ischemia Angina Pharmacology Stenosis 52

The British Journal of Cardiology

APRIL 2, 2025

Most services provided admission avoidance (96.5%), post-discharge checks (87%), pharmacological optimisation (99%), ongoing monitoring (82%) and palliative care (87%). Median wait time was 20 days, with substantially longer waits in many areas. All services accepted referrals from multiple sources.

Heart Failure 40

Heart Failure Preserved Ejection Fraction Nursing Pharmacology 40

Journal of the American Heart Association

JUNE 27, 2025

Activated fibroblasts from patients with myocardial infarction were detected by positron emission tomography/computed tomography with a [(18)F]‐labeled fibroblast activation protein inhibitor.ResultsOur results indicated that CD11b expression and the number of CD45+CD11b+bone marrow mononuclear cells were dramatically increased in the heart tissues (..)

Ischemia 40

Ischemia Myocardial Infarction Pharmacology Cardiac Function 40

Journal of the American Heart Association

JULY 14, 2025

ELABELA, an endogenous ligand for the G protein‐coupled receptor APJ (apelin peptide jejunum, apelin receptor), has multiple pharmacological activities for protecting the cardiovascular system. BackgroundAtherosclerosis is a progressive arterial disease characterized by chronic inflammation and plaque formation in blood vessel walls.

Atherosclerosis 40

Atherosclerosis Plaque Diet Pharmacology 40

Frontiers in Cardiovascular Medicine

NOVEMBER 19, 2024

However, efficient pharmacological methods to prevent and treat arrhythmic complications are still lacking. BackgroundThe mechanism underlying new-onset postoperative atrial fibrillation (POAF) in adult cardiac surgery is not well understood.

Atrial Fibrillation 59

Atrial Fibrillation Pharmacology Hospital Research 59

Circulation

DECEMBER 3, 2024

Critical components and policy initiatives include clinicians emphasizing the prevention of tobacco product initiation and supporting cessation with established pharmacological and behavioral tobacco dependence treatment therapies as primary goals for achieving an end to commercial tobacco and nicotine addiction.

Cardiovascular Disease 73

Cardiovascular Disease Cerebrovascular Disease Pharmacology Biomarkers 73

Frontiers in Cardiovascular Medicine

FEBRUARY 24, 2025

The increasing prevalence of heart failure (HF) has led to advancements in therapeutic strategies, including the development of new pharmacological treatments and the expansion of guideline recommendations across the spectrum of left ventricular ejection fractions.

Heart Failure 52

Heart Failure Heart Transplant Pharmacology Transplant 52

Frontiers in Cardiovascular Medicine

APRIL 28, 2025

Current treatment options primarily include pharmacological and non-pharmacological approaches. Heart failure (HF) represents the terminal stage of cardiovascular disease and remains a leading cause of mortality. Epidemiological studies indicate a high prevalence and mortality rate of HF globally.

Heart Failure 52

Heart Failure Pharmacology Transplant Cardiac Function 52

Heart BMJ

JUNE 26, 2025

The real-world effectiveness of these secondary prevention medications does, however, not solely rely on the pharmacological efficacy of the drugs, but also depends on patient adherence. In 2003, the WHO reported that only 50% of patients adhered to their prescribed treatment regimens.

Pharmacology 52

Pharmacology Cardiovascular Disease Outcomes 52

Frontiers in Cardiovascular Medicine

JULY 10, 2025

Contemporary therapeutic approaches predominantly target rhythm control via catheter ablation techniques and pharmacological interventions with antiarrhythmic agents. These pathways promote extracellular matrix deposition, fibroblast activation, and heterogeneous conduction, creating a substrate for AF maintenance.

Atrial Fibrillation 52

Atrial Fibrillation Electrophysiology Pharmacology Ablation 52

Journal of Cardiovascular Pharmacology

JULY 13, 2025

Takotsubo syndrome (TTS) is an acute stress-induced cardiomyopathy characterized by transient left ventricular dysfunction, often mimicking acute myocardial infarction but without obstructive coronary artery disease.

Coronary Artery Disease 40

Coronary Artery Disease Myocardial Infarction Arrhythmia Cardiomyopathy 40

Open Heart

MARCH 25, 2025

Background Current pharmacological approaches for the treatment of orthostatic hypotension (OH) may detrimentally affect supine blood pressure (BP). This side effect is often unacceptable and limits the utility of medical management.

Blood Pressure 52

Blood Pressure Pharmacology Hypertension 52

Frontiers in Cardiovascular Medicine

JANUARY 20, 2025

Genetic deletion of PCSK9 confers protection against post-infarct mortality, whereas pharmacological inhibition with Alirocumab fails to reproduce these benefits and may exacerbate cardiac dysfunction.

Myocardial Infarction 52

Myocardial Infarction Cardiac Function Cholesterol Pharmacology 52

HCPLive

JULY 10, 2025

1 To project anticipated improvements in treatment and outcomes under full implementation of US and European pharmacologic treatment recommendations, investigators conducted a simulation study using cross-sectional data from NHANES from January 2013 through March 2020. million US noninstitutionalized adults.

Public Health 52

Public Health Cholesterol CME Angina 52

Frontiers in Cardiovascular Medicine

JUNE 30, 2025

ObjectiveTo evaluate the effect of different pharmacological therapies for heart failure (HF) between the Black vs. White population.MethodWe included randomized controlled trials (RCT) of HF pharmacological therapies with explicit strata of Black or White adults in the primary or secondary analysis.

Pharmacology 52

Pharmacology Heart Failure Outcomes Hospital 52

Journal of Clinical Investigation - Cardiology

DECEMBER 17, 2024

We propose that the pharmacologic activation of Shp1 has the potential to fine tune neutrophil hyperinflammation that is central to the pathogenesis of ARDS.

Hemorrhage 52

Hemorrhage Pulmonary Pharmacology 52

Journal of Cardiovascular Pharmacology

JULY 17, 2025

Abstract: Phthalates, widely used as plasticizers in industrial and medical products, are increasingly recognized as cardiovascular health disruptors. Their ubiquity poses a significant threat, particularly to patients with or at risk of cardiovascular disease.

Biomarkers 40

Biomarkers Cardiovascular Disease Article 40

Journal of Cardiovascular Electrophysiology

MARCH 10, 2025

This constellation of disease states has its own unique epidemiologic features, pathophysiology, experimental and clinical mechanisms; and an increasing knowledge base with respect to clinical presentation, prognostic implications, and therapeutic options from pharmacologic advances and non-pharmacologic interventions.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Atrial Fibrillation Heart Failure Pharmacology 40

Frontiers in Cardiovascular Medicine

MAY 29, 2025

Key targets were screened using topological analysis. Differentially expressed genes (DEGs) between MI patients and controls were obtained using open-source datasets.

Myocardial Infarction 40

Myocardial Infarction Biomarkers Pharmacology Research 40

Frontiers in Cardiovascular Medicine

APRIL 21, 2025

BackgroundAtrial fibrillation (AF) exhibits gender disparities in prevalence, complications, pharmacological management, and ablation efficacy.

Risk Factors 52

Risk Factors Ablation Atrial Fibrillation Pharmacology 52

HCPLive

JULY 10, 2025

1 “However, this assumption is contrary to a growing body of evidence demonstrating that certain pharmacological therapies and aerobic exercise training may reduce the risk of worsening HF events and improve symptom burden and quality of life to a greater extent in frail individuals with HF than in nonfrail HF patients.”

Heart Failure 64

Heart Failure Preserved Ejection Fraction CME Outcomes 64

Journal of Cardiovascular Pharmacology

JUNE 15, 2025

Paraquat, a widely used herbicide, is known to induce oxidative stress and inflammation, which leads to myocardial injury. Klotho, a protein with antioxidative and anti-inflammatory properties, has garnered as a potential cardioprotective factor.

Article 40

Article 40

Journal of Cardiovascular Pharmacology

JUNE 4, 2025

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive, fatal disease. Dissociation of tetrameric transthyretin (TTR) is the triggering event in the pathogenic mechanism; destabilizing TTR mutations accelerate the process. The TTR stabilizers, tafamidis and acoramidis, are the only FDA approved treatments for patients with ATTR-CM.

Cardiomyopathy 40

Cardiomyopathy Article 40

Nature Reviews - Cardiology

FEBRUARY 6, 2025

In this Review, Dhaun and colleagues discuss the reasons for poor control of hypertension, such as therapeutic inertia and poor patient adherence, as well as novel pharmacological approaches to blood pressure lowering.

Blood Pressure 135

Blood Pressure Pharmacology Hypertension 135

Journal of Cardiovascular Pharmacology

JUNE 24, 2025

No abstract available

40

40

Journal of Cardiovascular Pharmacology

JUNE 17, 2025

Takotsubo syndrome (TTS) is a stress-induced cardiomyopathy which is associated with important morbidity and in-hospital mortality. Microvascular dysfunction, inflammation and fibrosis may play crucial roles in TTS pathophysiology.

Cardiac Function 40

Cardiac Function Cardiomyopathy Hospital Article 40